iTeos Therapeutics, Inc. (ITOS)

iTeos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	35	12.6	267.63	344.78	-
Revenue Growth (YoY)	177.89%	-95.29%	-22.38%	-	-
Gross Profit	35	12.6	267.63	344.78	-
Selling, General & Admin	49.08	50.4	43.95	40.51	15.34
Research & Development	142.73	109.77	96.19	59.37	29.61
Operating Expenses	191.81	160.17	140.13	99.87	44.95
Operating Income	-156.81	-147.57	127.5	244.9	-44.95
Interest & Investment Income	30.87	31.77	11.36	0.08	-
Other Non Operating Income (Expenses)	5.6	6.77	9.88	11.49	6.86
Pretax Income	-120.34	-109.03	148.74	256.46	-38.09
Income Tax Expense	14.07	3.61	52.08	41.94	-0.06
Net Income	-134.41	-112.64	96.65	214.52	-38.03
Preferred Dividends & Other Adjustments	-	-	-	-	5.37
Net Income to Common	-134.41	-112.64	96.65	214.52	-43.4
Net Income Growth	-	-	-54.95%	-	-
Shares Outstanding (Basic)	40	36	36	35	15
Shares Outstanding (Diluted)	40	36	38	38	15
Shares Change (YoY)	13.17%	-5.30%	-0.02%	150.49%	7336.28%
EPS (Basic)	-3.32	-3.15	2.72	6.10	-2.88
EPS (Diluted)	-3.32	-3.15	2.56	5.68	-2.88
EPS Growth	-	-	-54.93%	-	-
Free Cash Flow	-99.81	-106.72	-112.13	511.96	-25.53
Free Cash Flow Per Share	-2.47	-2.98	-2.97	13.55	-1.69
Gross Margin	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-448.03%	-1171.69%	47.64%	71.03%	-
Profit Margin	-384.04%	-894.34%	36.11%	62.22%	-
Free Cash Flow Margin	-285.18%	-847.34%	-41.90%	148.49%	-
EBITDA	-155.57	-146.68	128.3	245.5	-44.42
EBITDA Margin	-	-	47.94%	71.21%	-
D&A For EBITDA	1.24	0.9	0.8	0.6	0.54
EBIT	-156.81	-147.57	127.5	244.9	-44.95
EBIT Margin	-	-	47.64%	71.03%	-
Effective Tax Rate	-	-	35.02%	16.35%	-
Revenue as Reported	35	12.6	267.63	344.78	-

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q